People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Terns Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $97.7M | $2.9B | 2020 |
Yi Shi, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Yi Shi, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Kindler | 1 | 3 |
| David Fellows | 1 | 2 |
| Carl Gordon, Ph.D. | 1 | 2 |
| Elise Wang | 1 | 2 |
| Bryan Yoon | 1 | 1 |
| Hongbo Lu, Ph.D. | 1 | 1 |
| Senthil Sundaram | 1 | 1 |
| Weidong Zhong, Ph.D. | 1 | 1 |
| Jill Quigley | 1 | 1 |
| Mark Vignola, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.